• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    11/26/24 7:34:11 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care
    Get the next $HWH alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)

     

    HWH International Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    44852G101

    (CUSIP Number)

     

    Heng Fai Ambrose Chan

    Chairman

    HWH International Inc.

    4800 Montgomery Lane, Suite 210

    Bethesda, MD 20814

    Telephone: 301-971-3955

    (Name, Address and Telephone Number of Person Authorized to

    Receive Notices and Communications)

     

    November 25, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See section 240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or other subject to the liabilities of that section of Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 44852G101

     

    1

    Names of Reporting Person.

     

    Heng Fai Ambrose Chan

    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

    4

    Source of Funds (See Instructions)

     

    OO

    5

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6 Citizenship or Place of Organization
       
      Republic of Singapore

    Number of Shares

    Beneficially

    Owned by

    Each
    Reporting

    Person With

    7

    Sole Voting Power

     

    13,000 (1)

    8

    Shared Voting Power (see Item 5 below)

     

    23,926,331 (1)

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power (see Item 5 below)

     

    23,926,331 (1)

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    23,926,331 (1)

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    88.9% (2)

    14

    Type of Reporting Person

     

    IN

     

    (1) Includes (i) 2,330,155 shares and warrants convertible into 236,875 shares of the Issuer’s common stock, $0.0001 par value held by Alset Acquisition Sponsor, LLC; (ii) 13,000 shares of common stock owned directly by Mr. Chan; (iii) 9,958,347 shares of common stock held by Alset International Limited; and (iv) 11,387,954 shares of common stock held by Alset Inc., over which Mr. Chan may be deemed to possess indirect beneficial ownership as the Chief Executive Officer and Chairman of Alset Inc. and Alset International Limited.
    (2) Based on 26,669,602 shares of the Issuer’s common stock outstanding as of November 25, 2024.

     

     
     

     

    CUSIP No. 44852G101

     

    1

    Names of Reporting Person.

     

    Alset Inc.

    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

    4

    Source of Funds (See Instructions)

     

    OO

    5

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6 Citizenship or Place of Organization
       
      Texas

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power (see Item 5 below)

     

    23,913,331 (1)

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power (see Item 5 below)

     

    23,913,331 (1)

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    23,913,331 (1)

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    88.9% (1)(2)

    14

    Type of Reporting Person

     

    CO

     

    (1) Includes (i) 2,330,155 shares and warrants convertible into 236,875 shares of the Issuer’s common stock, $0.0001 par value held by Alset Acquisition Sponsor, LLC, a majority owned subsidiary of Alset Inc.; (ii) 9,958,347 shares held by Alset International Limited, a majority owned subsidiary of Alset Inc; and (iii) 11,387,954 shares held by Alset Inc. directly.
    (2) Based on 26,669,602 shares of the Issuer’s common stock outstanding as of November 25, 2024.

     

     
     

     

    CUSIP No. 44852G101

     

    1

    Names of Reporting Person.

     

    Alset International Limited

    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

    4

    Source of Funds (See Instructions)

     

    OO

    5

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6 Citizenship or Place of Organization
       
      Singapore

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7

    Sole Voting Power

     

    9,958,347

    8

    Shared Voting Power (see Item 5 below)

     

    0

    9

    Sole Dispositive Power

     

    9,958,347

    10

    Shared Dispositive Power (see Item 5 below)

     

    0

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    9,958,347

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    37.3% (1)

    14

    Type of Reporting Person

     

    CO

     

    (1) Based on 26,669,602 shares of the Issuer’s common stock outstanding as of November 25, 2024.

     

     
     

     

    CUSIP No. 44852G101

     

    1

    Names of Reporting Person.

     

    Alset Acquisition Sponsor, LLC

    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

    4

    Source of Funds (See Instructions)

     

    OO

    5

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6 Citizenship or Place of Organization
       
      Delaware

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7

    Sole Voting Power

     

    2,567,030(1)

    8

    Shared Voting Power (see Item 5 below)

     

    0

    9

    Sole Dispositive Power

     

    2,567,030(1)

    10

    Shared Dispositive Power (see Item 5 below)

     

    0

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,567,030(1)

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    9.5% (2)

    14

    Type of Reporting Person

     

    CO

     

    (1) Includes 2,330,155 shares and warrants convertible into 236,875 shares of the Issuer’s common stock
    (2) Based on 26,669,602 shares of the Issuer’s common stock outstanding as of November 25, 2024.

     

     
     

     

    Explanatory Note

     

    This Amendment No. 7 (this “Amendment”) amends and supplements the Schedule 13D/A filed on November 22, 2024 (the “Schedule 13D”) by Alset Acquisition Sponsor, LLC, a Delaware limited liability company (the “Sponsor”), Heng Fai Ambrose Chan, Alset Inc., a Texas company, and Alset International Limited, a company registered in Singapore (the “Reporting Persons”) relating to the Common Stock of HWH International Inc. (formerly, known as Alset Capital Acquisition Corp., and herein after referred to as the “Issuer”). This Amendment is made for the purposes of reporting that on November 25, 2024, Alset Inc. entered into a Stock Purchase Agreement with the Issuer, pursuant to which Alset Inc. agreed to purchase 4,411,764 newly issued shares of the Issuer’s common stock for a price of $0.68 per share.

     

    Information reported in the Schedule 13D/A remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Schedule 13D/A. All references in the Schedule 13D/A and this Amendment shall be deemed to refer to the Schedule 13D as amended and supplemented by this Amendment.

     

    SCHEDULE 13D

     

    This Schedule 13D/A is filed on behalf of Alset Acquisition Sponsor, LLC, a Delaware limited liability company (the “Sponsor”), Alset International Limited, a Singapore company, Alset Inc., a Texas corporation, and Heng Fai Ambrose Chan (collectively, the “Reporting Persons”).

     

    Item 1. Security and Issuer

     

    Securities disposed of: Common Stock, $0.0001 par value

     

      Issuer: HWH International Inc. (formerly known as Alset Capital Acquisition Corp., referred to herein as the “Issuer”),
        4800 Montgomery Lane, Suite 210
        Bethesda, MD 20814

     

    Item 2. Identity and Background

     

    (a) This statement is filed by:

     

      (i) Heng Fai Ambrose Chan is the Chief Executive Officer of both Alset Inc. and Alset International Limited, and is the majority stockholder of Alset Inc., which is the majority stockholder of Alset International Limited. Alset Inc. and Alset International Limited own the sole member of the Sponsor. Mr. Chan may be deemed to share beneficial ownership of the securities held of record by Alset Inc., Alset International Limited and the Sponsor, in addition to 13,000 shares he personally owns, for a total of 23,926,331 shares of the Issuer’s common stock. Mr. Chan disclaims any such beneficial ownership except to the extent of his pecuniary interest.
         
      (ii) Alset Inc. may be deemed to share beneficial ownership of the securities held of record by Alset International Limited and the Sponsor for a total of 23,913,331 shares of the Issuer’s common stock.
         
      (iii) Alset International Limited owns 9,958,347 shares of the Issuer’s common stock.
         
      (iv) The Sponsor owns 2,330,155 shares and warrants convertible into 236,875 shares of the Issuer’s common stock.

     

    All disclosures herein with respect to any Reporting Person are made only by the Reporting Person. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

      (b) The business address for Alset Inc. and Alset Acquisition Sponsor, LLC is 4800 Montgomery Lane, Suite 210, Bethesda, MD 20814. The business address for Mr. Chan and Alset International Limited is 9 Temasek Boulevard #16-04, Suntec Tower Two, Singapore 038989

     

      (c) The Sponsor’s principal business is to act as the Issuer’s sponsor in connection with the IPO (as defined below) and business combination. Alset Inc. is a diversified holding company. Alset International Limited is a Singapore-based holding company with interests in a variety of subsidiaries across several business sectors. Mr. Chan is the Chairman and Chief Executive Officer of Alset Inc. and Alset International Limited.

     

    (d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) None of the Reporting Persons has, during the last five years, been a party to civil proceeding of a judicial administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

     

    (f) Mr. Chan is a citizen of the Republic of Singapore. Alset Inc. is a Texas corporation. Alset International Limited is a Singapore company. The Sponsor is a Delaware limited liability company.

     

     
     

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Item 3 of the Schedule 13D is hereby amended to include the following:

     

    On November 25, 2024, Alset Inc. entered into a Stock Purchase Agreement with the Issuer, pursuant to which Alset Inc. agreed to purchase 4,411,764 newly issued shares of the Issuer’s common stock for a price of $0.68 per share.

     

    Item 4. Purpose of the Transaction

     

    Please refer to the disclosure provided in Item 3 above.

     

    Item 5. Interest in Securities of the Issuer

     

    (a)-(b) The aggregate number and percentage of Shares beneficially owned by the Reporting Persons (on the basis of a total of shares) are as follows:

     

    Heng Fai Ambrose Chan        
    a)   Amount beneficially owned: 23,926,331     Percentage: 88.9 %
    b)   Number of shares to which the Reporting Person has:        
      i. Sole power to vote or to direct the vote:     13,000  
      ii. Shared power to vote or to direct the vote:     23,926,331  
      iii. Sole power to dispose or to direct the disposition of:     13,000  
      iv. Shared power to dispose or to direct the disposition of:     23,926,331  

     

     
     

     

    Alset Inc.        
    a)   Amount beneficially owned: 19,501,567     Percentage: 88.9 %
    b)   Number of shares to which the Reporting Person has:        
    i.   Sole power to vote or to direct the vote:     0  
    ii.   Shared power to vote or to direct the vote:     23,913,331  
    iii.   Sole power to dispose or to direct the disposition of:     0  
    iv.   Shared power to dispose or to direct the disposition of:     23,913,331  

     

     

    Alset International Limited        
    a)   Amount beneficially owned: 9,958,347     Percentage: 37.3 %
    b)   Number of shares to which the Reporting Person has:        
    i.   Sole power to vote or to direct the vote:     0  
    ii.   Shared power to vote or to direct the vote:     9,958,347  
    iii.   Sole power to dispose or to direct the disposition of:     0  
    iv.   Shared power to dispose or to direct the disposition of:     9,958,347  

     

     

    Alset Acquisition Sponsor, LLC        
    a)   Amount beneficially owned: 2,567,030     Percentage: 9.5 %
    b)   Number of shares to which the Reporting Person has:        
    i.   Sole power to vote or to direct the vote:     0  
    ii.   Shared power to vote or to direct the vote:     2,567,030  
    iii.   Sole power to dispose or to direct the disposition of:     0  
    iv.   Shared power to dispose or to direct the disposition of:     2,567,030  

     

    Heng Fai Ambrose Chan has voting and dispositive power over the Shares held by Alset Inc., Alset International Limited and the Sponsor. As such, he may be deemed to have beneficial ownership of the Shares held directly by the Sponsor. Such person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

     

    (c) None of the Reporting Persons has effected any transactions of the Issuer’s Shares during the 60 days preceding the date of this report, except (i) as described in Item 6 of this Schedule 13D/A which information is incorporated herein by reference and (ii) as follows: On September 26, 2024, Alset Inc. entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with one of Alset Inc.’s subsidiaries, Alset International Limited. Pursuant to the Stock Purchase Agreement, Alset Inc. has purchased 6,500,000 shares (the “Shares”) of the Issuer. As consideration for the Shares, Alset Inc. issued a secured promissory note to Alset International Limited in the original principal amount of $4,095,000.00 (the “Promissory Note”). The Promissory Note bears an interest rate of 5% per annum and a maturity date of September 26, 2026, and is secured by collateral specified in a security agreement (the “Security Agreement”), between Alset Inc. and Alset International Limited. The closing of the transactions described above was contingent upon the approval of the stockholders of Alset International Limited, and the satisfaction of other closing conditions. The transactions closed on November 20, 2024.

     

    (d) Not applicable.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    Stock Loan Agreement

     

    Sponsor entered into an agreement effective January 30, 2024 (the “Agreement”), pursuant to which the Sponsor loaned a borrower (the “Borrower”) 347,220 shares of the Issuer’s common stock (the “Shares”). The Sponsor will retain the right to vote the Shares and receive any dividends paid on the Shares during the duration of the loan. The Borrower may not sell, lend or transfer the Shares. The Borrower has agreed not to buy, sell or short any securities of the Issuer for a period of one year from the date of the Agreement.

     

    Item 7. Material to be Filed as Exhibits

     

    Exhibit 10.1   Stock Purchase Agreement dated November 25, 2024, between Alset Inc. and HWH International Inc., incorporated by reference to Exhibit 10.1 to Alset Inc.’s current report on Form 8-K filed with the SEC on November 26, 2024.
    Exhibit 99.1   Joint Filing Agreement, by and between the Reporting Persons, dated January 19, 2024, incorporated by reference to Exhibit 99.1 to Schedule 13D/A filed by the Reporting Persons with the SEC on January 19, 2024.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Alset Inc.
       
    Date: November 26, 2024 By: /s/ Heng Fai Ambrose Chan
      Name: Heng Fai Ambrose Chan
      Title: Chief Executive Officer
         
      Alset International Limited
       
    Date: November 26, 2024 By: /s/ Heng Fai Ambrose Chan
      Name: Heng Fai Ambrose Chan
      Title: Chief Executive Officer
         
      Alset Acquisition Sponsor, LLC
         
    Date: November 26, 2024 By: /s/ Heng Fai Ambrose Chan
      Name: Heng Fai Ambrose Chan
      Title: Chief Executive Officer of Alset SPAC Group Inc., its Sole Member
         
    Date: November 26, 2024   /s/ Heng Fai Ambrose Chan
        Heng Fai Ambrose Chan

     

     

    Get the next $HWH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HWH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HWH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HWH International Inc. Announces Reverse Stock Split

      BETHESDA, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced a 1-for-5 reverse stock split of the Company's common stock to become effective at 9:00 a.m. (Eastern Time) on February 24, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on February 24, 2025, under the existing trading symbol "HWH." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 448

      2/20/25 8:50:00 AM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • D. Boral Capital Served as Placement Agent to HWH International Inc. (Nasdaq: HWH) in connection with its approximately $1.76 Million Public Offering

      BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,900, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,412,500 shares of common stock and 1,000,000 pre-funded warrants to purchase 1,000,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded

      1/7/25 11:18:56 AM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • HWH International Inc. Announces Closing of Approximately $1.76 Million Public Offering at $0.40 per Share

      BETHESDA, MD, Jan. 06, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,875, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,125,000 shares of common stock and 1,250,000 pre-funded warrants to purchase 1,250,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded w

      1/6/25 4:20:00 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by HWH International Inc.

      SC 13D/A - HWH International Inc. (0001897245) (Subject)

      11/26/24 7:34:11 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by HWH International Inc.

      SC 13D/A - HWH International Inc. (0001897245) (Subject)

      11/22/24 5:00:10 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HWH International Inc.

      SC 13G/A - HWH International Inc. (0001897245) (Subject)

      11/14/24 12:40:52 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Executive Chairman Chan Heng Fai Ambrose

      4 - HWH International Inc. (0001897245) (Reporting)

      4/2/25 8:37:43 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Director Chan Heng Fai Ambrose acquired 69,444 shares (SEC Form 4)

      4 - HWH International Inc. (0001897245) (Issuer)

      3/13/25 4:15:07 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Executive Chairman Chan Heng Fai Ambrose

      4 - HWH International Inc. (0001897245) (Reporting)

      1/28/25 9:36:07 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    Financials

    Live finance-specific insights

    See more
    • HWH International Inc. Acquires Café in South Korea, Unveiling Second Hapi Cafe Outlet

      Bethesda, MD, Feb. 26, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. ("HWH") (NASDAQ:HWH) proudly announces the acquisition of a café in Seocho-gu, South Korea, marking the launch of its second Hapi Cafe outlet in South Korea. HWH is delighted to reveal its latest acquisition of a café nestled in the heart of Seocho-gu, South Korea. This strategic move signifies HWH's dedication to providing unique and welcoming spaces where people can gather to savor food, coffee, and experiences. These cafes are a significant driver of our Health, Wealth, and Happiness vision to offer delicious and nutritious food and beverages to our customers and provide a platform where we can roll out lifestyle pr

      2/26/24 4:15:00 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chan Heng Fai Ambrose bought $585,000 worth of shares (1,300,000 units at $0.45) (SEC Form 4)

      4 - HWH International Inc. (0001897245) (Issuer)

      12/26/24 5:15:05 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Director Chan Heng Fai Ambrose bought $3,000,000 worth of shares (4,411,764 units at $0.68) (SEC Form 4)

      4 - HWH International Inc. (0001897245) (Issuer)

      11/26/24 7:12:12 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Chan Heng Fai Ambrose bought $3,801,758 worth of shares (6,034,537 units at $0.63) (SEC Form 4)

      4 - HWH International Inc. (0001897245) (Issuer)

      9/26/24 9:39:51 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    SEC Filings

    See more
    • SEC Form 10-Q filed by HWH International Inc.

      10-Q - HWH International Inc. (0001897245) (Filer)

      5/15/25 4:16:04 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • SEC Form SCHEDULE 13G filed by HWH International Inc.

      SCHEDULE 13G - HWH International Inc. (0001897245) (Subject)

      5/14/25 4:42:18 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-K filed by HWH International Inc.

      10-K - HWH International Inc. (0001897245) (Filer)

      3/31/25 4:05:57 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care